Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
09/2000
09/28/2000WO2000056403A1 UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE BY HMG-CoA REDUCTASE INHIBITORS
09/28/2000WO2000056363A1 Treatment of lfa-1 associated disorders with increasing doses of lfa-1 antagonist
09/28/2000WO2000056356A2 Induction of antigen-specific unresponsiveness by glioblastoma culture supernatants (gcs)
09/28/2000WO2000056350A2 Methods of use of beta 1-integrin inhibitors
09/28/2000WO2000056348A1 Inflammatory mediation obtained from atractylodes lancea
09/28/2000WO2000056346A1 Stable oil-in-glycerin emulsion
09/28/2000WO2000056336A2 Pharmaceutical compositions comprising a pyrimidine derivative and cyclodextrin
09/28/2000WO2000056335A1 Methods for treating neurodegenerative disorders using aspartyl protease inhibitors
09/28/2000WO2000056324A1 The use of certain affinity nmda antagonists as antidepressants
09/28/2000WO2000056314A1 Method of treating sleep apnoea
09/28/2000WO2000056304A2 Anti-inflammatory uses of manzamines
09/28/2000WO2000056301A2 Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
09/28/2000WO2000056292A2 Use of 1,2,4-triazolo[1,5-a]pyrimidine derivatives for treating migraine
09/28/2000WO2000056281A1 Composition for medicated chewing gums, process for manufacturing the same and tablets so obtained
09/28/2000WO2000041545A3 Regulators of the pct or smoothened pathway, compositions and uses related thereto
09/28/2000WO2000035428A3 Tricyclic nitrogen heterocycles as pde iv inhibitors
09/28/2000WO2000031253A3 Mutation of the parkin gene, compositions, methods and uses
09/28/2000WO2000029577A9 Novel members of the capsaicin/vanilloid receptor family of proteins and uses thereof
09/28/2000WO2000025767A3 Use of triphenylbutene derivatives for the treatment of neurological disorders
09/28/2000WO2000022142A3 Cell signaling polypeptides and nucleic acids
09/28/2000WO2000020447A3 Polynucleotides coding for secreted polypeptides, some having similarity to syncollin or claudin or cytokine, their therapeutic uses
09/28/2000WO2000015793A3 Human gpcr proteins
09/28/2000DE19913732A1 Nikotin-TTS mit einem Zusatz von Monoterpenketonen Nicotine TTS with an addition of monoterpene ketones
09/28/2000CA2669512A1 Human antibodies that bind human il-12 and methods for producing
09/28/2000CA2377383A1 Apoptosis related genes
09/28/2000CA2368916A1 49 human secreted proteins
09/28/2000CA2368229A1 50 human secreted proteins
09/28/2000CA2368223A1 48 human secreted proteins
09/28/2000CA2368210A1 50 human secreted proteins
09/28/2000CA2368187A1 Upregulation of type iii endothelial cell nitric oxide synthase by hmg-coa reductase inhibitors
09/28/2000CA2367985A1 Tetrahydropyran derivatives and their use as therapeutic agents
09/28/2000CA2367963A1 Hydroxamic and carboxylic acid derivatives
09/28/2000CA2367899A1 Triazolopyrimidinol compounds and salts thereof
09/28/2000CA2367866A1 Pyridine and pyrimidine derivatives and their use as inhibitors of cytokine mediated disease
09/28/2000CA2367699A1 Inflammatory mediation obtained from atractylodes lancea
09/28/2000CA2367488A1 Retroviral vectors comprising functional and non-functional splice donor and splice acceptor sites
09/28/2000CA2367464A1 Materials and methods relating to modulation of p66 expression
09/28/2000CA2367132A1 Induction of antigen-specific unresponsiveness by glioblastoma culture supernatants (gcs)
09/28/2000CA2367112A1 Methods for treating neurodegenerative disorders using aspartyl protease inhibitors
09/28/2000CA2367040A1 Pharmaceutical compositions comprising a pyrimidine derivative and cyclodextrin
09/28/2000CA2367025A1 Treatment of lfa-1 associated disorders with increasing doses of lfa-1 antagonist
09/28/2000CA2367022A1 Method of treating sleep apnoea
09/28/2000CA2367015A1 Methods of treating tardive dyskinesia and other movement disorders
09/28/2000CA2366845A1 Composition for medicated chewing gums, process for manufacturing the same and tablets so obtained
09/28/2000CA2366691A1 48 human secreted proteins
09/28/2000CA2366552A1 Method for detecting superantigen activity in a biological sample
09/28/2000CA2366132A1 48 human secreted proteins
09/28/2000CA2365255A1 Human tumor necrosis factor receptor tr9
09/28/2000CA2365247A1 49 human secreted proteins
09/28/2000CA2365243A1 Human transmembrane proteins
09/28/2000CA2365238A1 48 human secreted proteins
09/28/2000CA2365223A1 46 human secreted proteins
09/28/2000CA2365115A1 Compounds for use in therapy
09/28/2000CA2362700A1 Tricyclic indole-2-carboxylic acid compound used as nmda receptor antagonist
09/28/2000CA2361221A1 Novel protein which induces chondrocyte differentiation
09/28/2000CA2359568A1 The use of certain affinity nmda antagonists as antidepressants
09/27/2000EP1038880A2 Androstanes and pregnanes for allosteric modulation of GABA receptor
09/27/2000EP1038875A2 Imidazopyridine derivatives and process for making them
09/27/2000EP1038873A2 Benzo(3,4)cyclobuta(1,2-c)pyrrole derivatives as inhibitors of serotonine reuptake
09/27/2000EP1038872A1 4-Phenyl-4-heteroarylpiperdine derivatives as opioid receptor ligands
09/27/2000EP1038863A2 Substituted dimeric compounds, process for their preparation and pharmaceutical compositions thereof
09/27/2000EP1038528A1 Pentosan polysulfate containing medicament and implant for treating fibrosis
09/27/2000EP1038526A1 Treatment of functional disorders of the lower intestinal tract and subsequent visceral pain with moxonidine
09/27/2000EP1038522A2 Anticonvulsant enantiomeric amino acid derivatives
09/27/2000EP1038023A1 Agonists of metabotropic glutamate receptors and uses thereof
09/27/2000EP1038015A2 Mood disorder gene
09/27/2000EP1038002A1 Ubiquitin-like conjugating protein
09/27/2000EP1037993A2 A new gene called oligophrenin 1, its expression product, and the diagnostic and therapeutic applications thereof
09/27/2000EP1037970A1 Secreted proteins and polynucleotides encoding them
09/27/2000EP1037900A1 Kcnq2 and kcnq3-potassium channel genes which are mutated in benign familial neonatal convulsions (bfnc) and other epilepsies
09/27/2000EP1037894A1 Pharmaceuticals
09/27/2000EP1037892A1 Piperidine derivatives
09/27/2000EP1037890A1 Amino-benzothiazole derivatives
09/27/2000EP1037887A1 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha.-adrenoceptor agonists with improved metabolic stability
09/27/2000EP1037878A2 Metabotropic glutamate receptor antagonists for treating central nervous system diseases
09/27/2000EP1037876A1 Biphenyl derivatives as pharmaceuticals
09/27/2000EP1037874A1 1-(adamantyl)amidines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission
09/27/2000EP1037670A2 Agent for gene therapy of tumor, neurodegenerative, cardiovascular and autoimmune diseases
09/27/2000EP1037661A1 ribH
09/27/2000EP1037660A1 ribB
09/27/2000EP1037655A2 Methods of treatment using novel ligands of the neuropeptide receptor hfgan72 and agonists or antagonists thereof
09/27/2000EP1037654A1 ribA
09/27/2000EP1037653A1 Compositions and methods for regulating phagocytosis and icam-1 expression
09/27/2000EP1037646A1 Ginkgo biloba leaf extracts with a reduced 4'-o-methylpyridoxine and biflavone content
09/27/2000EP1037637A1 Use of 5ht1a receptor antagonists for preventing and/or treating temporal lobe epilepsy
09/27/2000EP1037630A2 Method for the treatment of disorders associated with apoptosis using n-heterocyclic glyoxylamide compounds
09/27/2000EP1037615A2 Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
09/27/2000EP1037612A1 Pharmaceutical compositions containing micronized bicyclic drugs
09/27/2000EP0885188B1 Hydroxyamidino derivatives useful as nitric oxide synthase inhibitors
09/27/2000EP0777488A4 Composition and method for allogeneic mononuclear cell immunotherapy
09/27/2000EP0773947B1 5H-THIAZOLO 3,2-a]PYRIMIDIN-5-ONE DERIVATIVES
09/27/2000EP0703915B1 Xamoneline tartrate
09/27/2000CN1268175A Catalytic monoclonal antibodies with protease activity for the selective lysis of the protein component of plaques and aggregates related to pathological conditions
09/27/2000CN1268138A Compounds
09/27/2000CN1268137A Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
09/27/2000CN1268136A Substituted 4-oxo-napthyridine-3-carboxamides as gaba brain receptor ligands
09/27/2000CN1268133A 2-Aminopyridines containing fused ring substituents as NOS inhibitors
09/27/2000CN1268124A Derivatives of acyl-piperazinil-pyrimidins, preparation thereof and application as medicaments
09/27/2000CN1268122A Branched alkoxy- substituted 2-aminopyridines as NOS inhibitors
09/27/2000CN1268121A Crystalline 10,10-bis ((2-fluoro-4-pyridinyl) methyl)-9 (10H)-anthraclnone and an improved process for preparing the same
1 ... 1483 1484 1485 1486 1487 1488 1489 1490 1491 1492 1493 1494 1495 1496 1497 1498 1499 1500 1501 1502 1503 ... 1833